ArticleOncotarget2016
Metformin and cancer: Quo vadis et cui bono?
Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- TheFrontiers in oncology · 2019Article
- Article
- Metformin directly targets the H3K27me3 demethylase KDM6A/UTX.Aging cell · 2018Article
- Glyoxalase 1 sustains the metastatic phenotype of prostate cancer cells via EMT control.Journal of cellular and molecular medicine · 2018Article
- Development of an Injectable Slow-Release Metformin Formulation and Evaluation of Its Potential Antitumor Effects.Scientific reports · 2018Article
- Metformin Potentiates the Benefits of Dietary Restraint: A Metabolomic Study.International journal of molecular sciences · 2017Article
- Metformin inhibits RANKL and sensitizes cancer stem cells to denosumab.Cell cycle (Georgetown, Tex.) · 2017Article
- Unveiling changes in the landscape of patient populations in cancer early drug development.Oncotarget · 2017Review
- Review
- Rosiglitazone reduces breast cancer risk in Taiwanese female patients with type 2 diabetes mellitus.Oncotarget · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
How many lives have already been saved by the anti-cancer drug metformin? Inadvertently perhaps, among the millions of type 2 diabetics with occult or known cancers and who have been prescribed metformin since the 1950s, thousands may have benefited from the anticancer properties of this first-line pharmacotherapy. Quo vadis? Now, researchers aim to move metformin from a non-targeted stage of cancer therapy that has been mostly developed retrospectively and empirically into a targeted therapy by following a biological rationale and a predefined mechanism of action. But, who might benefit from metformin? Cui bono? Because metformin is on the leading edge of a new generation of cancer metabolism-targeted therapies, perhaps it is the right time to provide solutions to the challenges that metformin and other onco-biguanides will face in the coming years before becoming incorporated into the therapeutic armamentarium against cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.